转移性骨肿瘤治疗新突破

Development of treatment in metastatic turnors involving bone

骨骼是恶性肿瘤最常见的转移部位之一,对转移性骨肿瘤的治疗已成为当今肿瘤学研究的热点之一。骨保护素(OPG)、核因子κB受体活化因子配体(RANKL)及核因子κB受体活化因子(RANK)的骨调节轴即OPG/RANKL/RANK,是影响破骨细胞分化、成熟的重要途径。安进公司开发的完全人源化RANKL抗体denosumab,可通过阻止RANKL和RANK结合抑制破骨细胞形成,从而实现肿瘤骨转移治疗的新突破。本文详细介绍OPG/RANKL/RANK及denosumab的作用机制以及相关大规模临床研究。

The receptor activator of nuclear factor-κB ligand(RANKL),its cognate receptor RANK,and its natural decoy receptor,osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption.The only step remaining in the development of a clinical intervention is the generation of a safe,effective,and specific drug that can inhibit RANKL in humans.Here we review the clinical development of denosumab,which is a fully human mAb directed against RANKL.This review includes the current c...